All In Biotech

Drug Trial Radar · NCT04665206

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

Phase I/II, Multi-Center, Open-Label Study of VT3989, Alone or in Combination, in Patients With Locally Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

474

Planned (sponsor's estimate)

Start

Mar 24, 2021

Primary completion

Nov 2, 2029

Study completion Mar 2, 2030

Sponsor

Lead sponsor
Vivace Therapeutics, IncIndustry
Sponsor type
Industry
First posted
Dec 11, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which no effective standard therapy is available.

Conditions

  • Solid Tumor, Adult
  • Mesothelioma
  • NSCLC
  • Pleural Mesothelioma
  • Non-Pleural Mesothelioma
  • Non Small Cell Lung Cancer
  • Epithelioid Hemangioendothelioma (EHE)
  • Adenoma
  • Neoplasms
  • Neoplasms, Glandular and Epithelial
  • Neoplasms by Histologic Type
  • Neoplasms, Mesothelial

Interventions

  • VT3989Drug

    25, 50, 100, 150 or 200 mg for oral administration.

  • Nivolumab & IpilimumabDrug

    Nivolumab infusion - 360 mg every 3 weeks, 30-minute intravenous infusion Ipilimumab infusion - 1 mg/kg every 6 weeks, 30-minute intravenous infusion

  • OsimertinibDrug

    40 or 80 mg tablets for oral administration

  • Pemetrexed/CarboplatinDrug

    Pemetrexed infusion: 500 mg/m2 intravenous infusion Carboplatin infusion: AUC 5.0 intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of Dose Limiting ToxicityTime frame: over the first 21 days of dosing
  2. Occurrence of General ToxicityTime frame: through study completion, an average of 30 months

Locations

12 sites in 2 countries. Site status is shown where the registry gives one.

  • UCSF Helen Diller Family Comprehensive Cancer Center

    San Francisco, California · Recruiting

  • University of Chicago Medical Center

    Chicago, Illinois · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • M Health Fairview University of Minnesota Medical Center

    Minneapolis, Minnesota · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • NEXT Oncology

    San Antonio, Texas · Recruiting

  • Virginia Cancer Specialists, PC

    Arlington, Virginia · Recruiting

  • Monash Health

    Clayton, Victoria, Australia · Recruiting

  • Peter MacCullum Cancer Centre

    Melbourne, Victoria, Australia · Recruiting

  • Linear Clinical Research

    Nedlands, Western Australia, Australia · Terminated

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.